319 related articles for article (PubMed ID: 12719580)
1. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
Zwick MB; Parren PW; Saphire EO; Church S; Wang M; Scott JK; Dawson PE; Wilson IA; Burton DR
J Virol; 2003 May; 77(10):5863-76. PubMed ID: 12719580
[TBL] [Abstract][Full Text] [Related]
2. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.
Wilkinson RA; Piscitelli C; Teintze M; Cavacini LA; Posner MR; Lawrence CM
J Virol; 2005 Oct; 79(20):13060-9. PubMed ID: 16189008
[TBL] [Abstract][Full Text] [Related]
3. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA
Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595
[TBL] [Abstract][Full Text] [Related]
6. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
7. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
8. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
Zwick MB; Komori HK; Stanfield RL; Church S; Wang M; Parren PW; Kunert R; Katinger H; Wilson IA; Burton DR
J Virol; 2004 Mar; 78(6):3155-61. PubMed ID: 14990736
[TBL] [Abstract][Full Text] [Related]
9. Improvement in affinity and HIV-1 neutralization by somatic mutation in the heavy chain first complementarity-determining region of antibodies triggered by HIV-1 infection.
Torán JL; Sánchez-Pulido L; Kremer L; del Real G; Valencia A; Martínez-A C
Eur J Immunol; 2001 Jan; 31(1):128-37. PubMed ID: 11169446
[TBL] [Abstract][Full Text] [Related]
10. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
Wu L; Zhou T; Yang ZY; Svehla K; O'Dell S; Louder MK; Xu L; Mascola JR; Burton DR; Hoxie JA; Doms RW; Kwong PD; Nabel GJ
J Virol; 2009 May; 83(10):5077-86. PubMed ID: 19264769
[TBL] [Abstract][Full Text] [Related]
11. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
Wu X; Zhou T; Zhu J; Zhang B; Georgiev I; Wang C; Chen X; Longo NS; Louder M; McKee K; O'Dell S; Perfetto S; Schmidt SD; Shi W; Wu L; Yang Y; Yang ZY; Yang Z; Zhang Z; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Simek M; Burton DR; Koff WC; Doria-Rose NA; Connors M; ; Mullikin JC; Nabel GJ; Roederer M; Shapiro L; Kwong PD; Mascola JR
Science; 2011 Sep; 333(6049):1593-602. PubMed ID: 21835983
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody.
Clark KR; Walsh ST
Protein Sci; 2009 Dec; 18(12):2429-41. PubMed ID: 19785005
[TBL] [Abstract][Full Text] [Related]
13. Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig.
Neshat MN; Goodglick L; Lim K; Braun J
Int Immunol; 2000 Mar; 12(3):305-12. PubMed ID: 10700465
[TBL] [Abstract][Full Text] [Related]
14. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
15. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
Calarese DA; Scanlan CN; Zwick MB; Deechongkit S; Mimura Y; Kunert R; Zhu P; Wormald MR; Stanfield RL; Roux KH; Kelly JW; Rudd PM; Dwek RA; Katinger H; Burton DR; Wilson IA
Science; 2003 Jun; 300(5628):2065-71. PubMed ID: 12829775
[TBL] [Abstract][Full Text] [Related]
16. Increasing the potency and breadth of an HIV antibody by using structure-based rational design.
Diskin R; Scheid JF; Marcovecchio PM; West AP; Klein F; Gao H; Gnanapragasam PN; Abadir A; Seaman MS; Nussenzweig MC; Bjorkman PJ
Science; 2011 Dec; 334(6060):1289-93. PubMed ID: 22033520
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction.
Hinz A; Lutje Hulsik D; Forsman A; Koh WW; Belrhali H; Gorlani A; de Haard H; Weiss RA; Verrips T; Weissenhorn W
PLoS One; 2010 May; 5(5):e10482. PubMed ID: 20463957
[TBL] [Abstract][Full Text] [Related]
18. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
Julien JP; Huarte N; Maeso R; Taneva SG; Cunningham A; Nieva JL; Pai EF
J Virol; 2010 May; 84(9):4136-47. PubMed ID: 20147404
[TBL] [Abstract][Full Text] [Related]
19. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes.
Dorgham K; Dogan I; Bitton N; Parizot C; Cardona V; Debré P; Hartley O; Gorochov G
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):82-92. PubMed ID: 15665647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
